WORCESTER, Mass. and TORONTO, Nov. 21, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) (www.generex.com) announced today that its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), will present new Phase 2 clinical data from its study of a novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine (AE37) in HER-2 expressing breast cancer patients at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas on December 7, 2011.
Antigen Express also announced the notification of a decision to grant a patent by the Japanese Patent Office relating to the Company's core Ii-Key Hybrid technology platform.
Data Presentation at SABCS
Authors: Diane F. Hale; Sonia A. Perez; Alan K. Sears; Guy T. Clifton; Timothy J. Vreeland; Jarrod P. Holmes; Alexandros Ardavanis; Nikos Pistamaltzian; Giannis Rellias; Sathibalan Ponniah; Michael Papamichail; George E. Peoples; Elizabeth A. Mittendorf
Title: "An Update of a Phase II Trial of the HER2 Peptide AE37 Vaccine in Breast Cancer Patients to Prevent Recurrence"
Poster Session I: Treatment - Therapeutic Strategies: Immunotherapy (P1-13-01)
Session Date and Time: Wednesday, December 7, 2011, 5:00 p.m. – 7:00 p.m. Central Time
Location: Henry B. Gonzalez Convention Center, San Antonio, Texas, Exhibit Halls A-B
About AE37 and Ii-Key Hybrid Platform Technology
Antigen Express is a platform technology and product-based company developing proprietary vaccine formulations for large, unmet medical needs. The Company's Ii-Key Hybrid technology platform entails the modificatio
|SOURCE Generex Biotechnology Corporation|
Copyright©2010 PR Newswire.
All rights reserved